Cognitive Behavioral Therapy
Published assessmentPublished Oct 16, 2026 · revision 3
Major Depressive Disorder care options
We show care options we have checked for this need. We may not have all options. This page cannot tell you which is best for you.
Published Oct 16, 2026Revision 4 · EveryOptionEnglish (United States)
Published treatment options
These are the options we have published. This order does not say which is best for you.
Assessment for Major Depressive Disorder
Fluoxetine
Published assessmentPublished Sep 20, 2026 · revision 1
Sertraline
Published assessmentPublished Sep 20, 2026 · revision 1
Not reviewed means no current published assessment for the exact pair. No published conclusion means an assessment exists without a research conclusion. Neither establishes benefit or no benefit.
Cognitive Behavioral Therapy for Major Depressive Disorder
This assessment belongs to this exact Treatment and Need. It does not extend its conclusion to other populations or formats.
Research suggests benefit in this exact scope
Published Oct 16, 2026 · revision 3
What research says
NIMH identifies cognitive behavioral therapy as an evidence-based therapy for depression. This bounded assessment does not compare every option or determine personal suitability.
NIMH Depression · checked Oct 2, 2026
Relationship: supports bounded conclusion
Statement scope
- Formulation or format
psychotherapy; in-person or virtual delivery is described generally, with no CBT-specific delivery restriction stated
- Indication
depression
- Need
Major Depressive Disorder
- Population
people with depression; no further population or severity restriction stated
Source collection coverage: need:major-depressive-disorder
Pointer: /publication/treatmentExcerpt
Open sourceDelivery and time commitment
Canada’s CANMAT 2023 guideline for adults with major depressive disorder reports that twice-weekly CBT sessions for depression show improved outcomes compared with once-weekly sessions. This describes session frequency in the evidence the guideline reviewed; a local provider’s schedule and an individual’s needs may differ.
Official guideline documents · checked Oct 6, 2026
Relationship: supports the attributed comparison of twice-weekly with once-weekly CBT sessions
Statement scope
- Formulation or format
psychological treatment sessions of CBT and IPT
- Guideline
CANMAT 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults
- Indication
major depressive disorder
- Population
Adults with major depressive disorder covered by the CANMAT 2023 guideline
- Section
Q.3.d. How Many Sessions of Psychological Treatment are Required?
Source collection coverage: global
Pointer: /document/passage/text
Open sourceFluoxetine for Major Depressive Disorder
This assessment belongs to this exact Treatment and Need. It does not extend its conclusion to other populations or formats.
Research suggests benefit in this exact scope
Published Sep 20, 2026 · revision 1
What research says
The retained fluoxetine label reports placebo-controlled studies for major depressive disorder; this assessment does not determine personal suitability or compare fluoxetine with every alternative.
DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026
Relationship: supports bounded conclusion
Statement scope
- Jurisdiction
United States label
- Need
Major Depressive Disorder
- Population
source-defined study populations
Source collection coverage: country:US
Pointer: /sections/4
Supporting passage: The efficacy of fluoxetine was studied in 5- and 6-week placebo-controlled trials with depressed adult and geriatric outpatients (≥ 18 years of age) whose diagnoses corresponded most closely to the DSM-III (currently DSM-IV) category of MDD.
Open sourceSertraline for Major Depressive Disorder
This assessment belongs to this exact Treatment and Need. It does not extend its conclusion to other populations or formats.
Research suggests benefit in this exact scope
Published Sep 20, 2026 · revision 1
What research says
The current ZOLOFT label reports randomized, double-blind, placebo-controlled studies supporting its MDD evidence scope. This bounded assessment does not compare every option or determine personal suitability.
DailyMed sertraline (Zoloft) label · checked Oct 16, 2026
Relationship: supports bounded conclusion
Statement scope
- Completeness
Not assessed
- Need
Major Depressive Disorder
- Population
source-defined population
Source collection coverage: country:US
Pointer: /sections/1
Supporting passage: The efficacy of ZOLOFT as a treatment for MDD was established in two randomized, double-blind, placebo-controlled studies and one double-blind, randomized-withdrawal study following an open label study in adult (ages 18 to 65) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria for MDD (studies MDD-1 and MDD-2).
Open sourceCoverage
These are the three options EveryOption has published for Major Depressive Disorder: fluoxetine, sertraline, and cognitive behavioral therapy. This is not a complete list of treatments.
DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026
Relationship: supports published option coverage
Statement scope
- Jurisdiction
United States label
- Need
Major Depressive Disorder
- Population
source-defined study populations
Source collection coverage: country:US
Pointer: /sections/4
Supporting passage: The efficacy of fluoxetine was studied in 5- and 6-week placebo-controlled trials with depressed adult and geriatric outpatients (≥ 18 years of age) whose diagnoses corresponded most closely to the DSM-III (currently DSM-IV) category of MDD.
Open sourceDailyMed sertraline (Zoloft) label · checked Oct 16, 2026
Relationship: supports published option coverage
Statement scope
- Completeness
Not assessed
- Need
Major Depressive Disorder
- Population
source-defined population
Source collection coverage: country:US
Pointer: /sections/1
Supporting passage: The efficacy of ZOLOFT as a treatment for MDD was established in two randomized, double-blind, placebo-controlled studies and one double-blind, randomized-withdrawal study following an open label study in adult (ages 18 to 65) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria for MDD (studies MDD-1 and MDD-2).
Open sourceNIMH Depression · checked Oct 2, 2026
Relationship: supports published option coverage
Statement scope
- Formulation or format
psychotherapy; in-person or virtual delivery is described generally, with no CBT-specific delivery restriction stated
- Indication
depression
- Need
Major Depressive Disorder
- Population
people with depression; no further population or severity restriction stated
Source collection coverage: need:major-depressive-disorder
Pointer: /publication/treatmentExcerpt
Open sourceAccess
These are the options and access paths EveryOption has published for Denver for Major Depressive Disorder. This is not complete coverage of the condition or the city.
Provider-owned websites · checked Sep 21, 2026
Relationship: supports Denver access navigation
Statement scope
- Geography
Denver, Colorado, United States
- Need
Major Depressive Disorder
- Treatment
Cognitive Behavioral Therapy
Source collection coverage: global
Pointer: /statements/0/text
Open sourceFind care
Open the published Denver result for this Need and treatment. It is one sourced path, not complete coverage or a statement of current availability.
You can also look for documented medication evaluation or ongoing management for Major Depressive Disorder, without selecting a specific medication.
Find medication servicesPublished relationship sources
These sources explain why each Treatment is listed for this Need. They are separate from its exact-pair assessment.
Cognitive Behavioral Therapy for Major Depressive Disorder
NIMH Depression · checked Sep 20, 2026
Relationship: source-described CBT relationship for the Need
Statement scope
- Completeness
Not assessed
- Need
Major Depressive Disorder
- Population
source-defined population
Source collection coverage: need:major-depressive-disorder
Pointer: /publication/treatmentExcerpt
Open sourceFluoxetine for Major Depressive Disorder
DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026
Relationship: label-reported clinical studies for the Need
Statement scope
- Jurisdiction
United States label
- Need
Major Depressive Disorder
- Population
source-defined study populations
Source collection coverage: country:US
Pointer: /sections/4
Supporting passage: The efficacy of fluoxetine was studied in 5- and 6-week placebo-controlled trials with depressed adult and geriatric outpatients (≥ 18 years of age) whose diagnoses corresponded most closely to the DSM-III (currently DSM-IV) category of MDD.
Open sourceSertraline for Major Depressive Disorder
DailyMed sertraline (Zoloft) label · checked Oct 16, 2026
Relationship: label-reported clinical studies for the Need
Statement scope
- Completeness
Not assessed
- Need
Major Depressive Disorder
- Population
source-defined population
Source collection coverage: country:US
Pointer: /sections/1
Supporting passage: The efficacy of ZOLOFT as a treatment for MDD was established in two randomized, double-blind, placebo-controlled studies and one double-blind, randomized-withdrawal study following an open label study in adult (ages 18 to 65) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) criteria for MDD (studies MDD-1 and MDD-2).
Open sourceSee something wrong? Tell us. Your note is private. We check sources before we change this page.